Related Experiment Video

Updated: Nov 19, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.8K

DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?

Alicja Krejner-Bienias1, Katarzyna Grzela2, Tomasz Grzela3

  • 1Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland.

Archivum Immunologiae Et Therapiae Experimentalis
|February 2, 2021
PubMed

Insights

Type 2 diabetes impacts COVID-19 severity. Dipeptidyl peptidase 4 (DPP4) may influence SARS-CoV-2 infection, necessitating research into DPP4 inhibitors (gliptins) for diabetic patients.

Area of Science:

  • Virology
  • Endocrinology
  • Immunology

Background:

  • COVID-19, a novel coronavirus disease, presents a global health challenge.
  • Comorbidities, particularly type 2 diabetes, significantly affect COVID-19 clinical outcomes.
  • Dipeptidyl peptidase 4 (DPP4) is implicated in diabetes pathophysiology and may influence SARS-CoV-2 infection course.

Purpose of the Study:

  • To review the potential role of dipeptidyl peptidase 4 (DPP4) modulation in SARS-CoV-2 infection.
  • To clarify the impact of DPP4 inhibitors (gliptins) on COVID-19 course in diabetic patients.

Main Methods:

  • Literature review of structural studies and clinical data.
  • Analysis of the interaction between DPP4, SARS-CoV-2, and type 2 diabetes.

Main Results:

  • DPP4's role in diabetes pathophysiology suggests a potential link to COVID-19 severity.
  • The widespread use of DPP4 inhibitors (gliptins) in diabetic populations warrants investigation.

Conclusions:

  • Further research is crucial to understand DPP4's exact role in SARS-CoV-2 infection.
  • Clarifying DPP4 modulation's impact is essential for managing COVID-19 in patients with type 2 diabetes.
Keywords:
COVID-19DPP4DiabetesGliptinsSARS-CoV-2

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses05:49

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

2.1K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
348
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
576
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
78
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
333
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
85
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K